2021
iRGD‐Liposomes Enhance Tumor Delivery and Therapeutic Efficacy of Antisense Oligonucleotide Drugs against Primary Prostate Cancer and Bone Metastasis
Guan J, Guo H, Tang T, Wang Y, Wei Y, Seth P, Li Y, Dehm S, Ruoslahti E, Pang H. iRGD‐Liposomes Enhance Tumor Delivery and Therapeutic Efficacy of Antisense Oligonucleotide Drugs against Primary Prostate Cancer and Bone Metastasis. Advanced Functional Materials 2021, 31 PMID: 34211360, PMCID: PMC8240484, DOI: 10.1002/adfm.202100478.Peer-Reviewed Original ResearchAndrogen receptorProstate cancerSubcutaneous xenograftsSolid tumorsAR splice variantsHigh loading efficiencySignificant side effectsProstate cancer treatmentPrimary prostate cancerBone metastasesAR expressionLoading efficiencyEfficient knockdownTumor deliverySide effectsProstate tumorsTherapeutic efficacyTumor growthTreatment studiesTumor tissueAntisense oligonucleotide drugXenograftsAntitumor efficacyCancer treatmentMetastasis
2019
Tumor-specific macrophage targeting through recognition of retinoid X receptor beta
Tang T, Wei Y, Kang J, She Z, Kim D, Sailor M, Ruoslahti E, Pang H. Tumor-specific macrophage targeting through recognition of retinoid X receptor beta. Journal Of Controlled Release 2019, 301: 42-53. PMID: 30871996, PMCID: PMC6500479, DOI: 10.1016/j.jconrel.2019.03.009.Peer-Reviewed Original ResearchConceptsRetinoid X receptor betaTumor macrophagesSystemic administrationReceptor betaNormal macrophage functionCancer therapyTumor-bearing miceTumor-selective bindingCell surface markersNovel cell surface markersMacrophage modulationMacrophage functionSolid tumorsTumor-specific mannerMacrophage typesSurface markersMacrophagesCancer progressionTumorsHealthy organsNuclear receptorsTherapyAdministrationCell surface localizationReceptors